新闻
AVDL
--
0.00%
--
Avadel将在美国神经病学会2021年年会上展示FT218关键REST-ON 3期研究的新数据
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with
Benzinga · 6天前
全球雷贝拉唑市场趋势,报告探索了关键地区,领先国家,公司,消费,驱动因素,部队分析,收入,机遇和挑战2021至2025年
Apr 07, 2021 (The Expresswire) -- Global "Rabeprazole Market" (2021-2025) Industry Research Report is a professional and in-depth study on the current state...
The Express Wire · 04/07 06:04
在预测期内2021-2026,重症肌无力治疗市场规模将以7.8%的复合年增长率增长
Apr 06, 2021 (The Expresswire) -- Myasthenia Gravis Treatment Market size was valued at $1.6 billion by 2020 and is anticipated to reach $2.2 billion by 2026...
The Express Wire · 04/06 18:41
全球临床营养市场规模,份额在2019-2028年将以5.27%的复合年增长率增长
Mar 25, 2021 (Market Insight Reports) -- Selbyville, Delaware. The report Clinical Nutrition Market Size and Analysis maintains enhanced dynamics and is...
Market Insight Reports · 03/25 12:50
分析师提供有关医疗保健公司的见解:Avadel Pharmaceuticals(AVDL)和GenMark(GNMK)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL) and GenMark (GNMK) with
SmarterAnalyst · 03/23 09:03
雷贝拉唑市场前景2021-2025:全球行业趋势分析,挑战和驱动因素,份额,到2025年的增长预测
Mar 19, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global "Rabeprazole Market" report...
The Express Wire · 03/19 06:16
在预测期内2021-2026,重症肌无力治疗市场规模将以7.8%的复合年增长率增长
ABNewswire · 03/18 23:42
Nocturia 2021年市场规模研究结果,市场增长因素分析和预测– 2027年增长最快的公司
Mar 18, 2021 (The Expresswire) -- In 2021 ,, “ Nocturia Market “ Size, Status and Market Insights, Forecast to 2027 Nocturia, also called nycturia (Greek...
The Express Wire · 03/18 07:51
LifeSci Capital维持对Avadel Pharmaceuticals(AVDL)的买入评级
SmarterAnalyst · 03/16 09:05
HC Wainwright&Co将DJ Avadel Pharmaceuticals的目标股价从15.00美元上调至17.00美元/股。
Dow Jones · 03/10 11:23
HC Wainwright&Co.维持DJ Avadel Pharmaceuticals的买入评级。
Dow Jones · 03/10 11:23
Avadel Pharmaceuticals(AVDL)获得Oppenheimer的买入评级
Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Avadel Pharmaceuticals (AVDL) today and set a price target of $19.00. The company's
SmarterAnalyst · 03/09 21:45
10-K:AVADEL PHARMACEUTICALS PLC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. MANAGEMENT'S DISCUSSION AND...
Edgar Online - (EDG = 10Q, 10K) · 03/09 21:11
8-K:AVADEL PHARMACEUTICALS PLC
(EDGAR Online via COMTEX) -- 0001012477 false 0001012477 2021-03-09 2021-03-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/09 14:13
重症肌无力治疗市场的全球趋势,市场份额,行业规模,增长,机会和市场预测2020至2027
Mar 09, 2021 (Market Insight Reports) -- The report for Myasthenia Gravis Treatment offers an assiduous analysis of contemporary market trends, driving...
Market Insight Reports · 03/09 12:48
BRIEF-Avadel Pharmaceuticals Provides Corporate Update And Reports Q4 And Full Year 2020 Financial Results
reuters.com · 03/09 12:44
Avadel Pharmaceuticals Q4每股收益($ 0.19)超出预期($ 0.27)
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent. This is a 171.43 percent decrease over losses of $(0.07) per
Benzinga · 03/09 12:26
智通港美股会议日历|3月9日
智通财经网 · 03/08 16:01
生物技术的未来一周(3月7日至13日):会议演讲和更多收益
Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA...
Benzinga · 03/06 15:57
Avadel Pharmaceuticals在临床治疗学杂志上重点报道了一次FT218药代动力学研究
DUBLIN, Ireland, March 02, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat
Benzinga · 03/02 13:11
微牛提供丰富的实时AVDL股票新闻,让你可以通过多个平台了解AVDL股票行情最新动态,这些免费的Avadel制药新闻可以帮助你做出明智投资。
AVDL 简况
Avadel Pharmaceuticals plc是一家生物制药公司。该公司的主要候选药物FT218是每晚一次研究性的羟丁酸钠制剂,用于治疗嗜睡症患者的过度白天嗜睡(EDS)和瘫痪。它的Micropump允许开发药物的改良或控释固体口服制剂。其LiquiTime技术允许开发液体悬浮液制剂中的改良或控释口服产品,这类产品尤其适合吞咽药品或胶囊有困难的儿童或患者。其Medusa技术能够开发延伸或改良过的注射剂型。